Form 4 for KROS Keros Therapeutics, Inc.
Accepted 2022-11-30 00:00:00 ET · period of report 2022-11-29 · accession 0001209191-22-059053 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2022-11-30 | 2022-11-29 | KROS | Pontifax Late Stage GP Ltd. | 10% | X - OptEx | $0.00 | -7,176 | 1.12M | -0.6% | $0 |
| DMI | 2022-11-30 | 2022-11-29 | KROS | Pontifax Late Stage GP Ltd. | 10% | X - OptEx | $0.00 | -7,176 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-29 | X | D | 1,914 | $0.00 | 1,226,412 | I See footnote | — | — | (F4) The securities are held by China IV. Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. |
| 2 | Common | Common Stock | 2022-11-29 | X | D | 3,539 | $0.00 | 2,284,612 | I See footnote | — | — | (F2) The securities are held by Israel IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. |
| 3 | Common | Common Stock | 2022-11-29 | X | D | 1,723 | $0.00 | 1,121,045 | I See footnote | — | — | (F3) The securities are held by Cayman IV. Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. |
| 4 | Derivative | Call Options (obligation to sell) | 2022-11-29 | X | D | 1,723 | $0.00 | 0 | I See footnote | $0.00 · — to 2023-10-07 | 1,723 Common Stock | (F3) The securities are held by Cayman IV. Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. (F5) Fully vested and exercisable. |
| 5 | Derivative | Call Options (obligation to sell) | 2022-11-29 | X | D | 3,539 | $0.00 | 0 | I See footnote | $0.00 · — to 2023-10-07 | 3,539 Common Stock | (F2) The securities are held by Israel IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. (F5) Fully vested and exercisable. |
| 6 | Derivative | Call Options (obligation to sell) | 2022-11-29 | X | D | 1,914 | $0.00 | 0 | I See footnote | $0.00 · — to 2023-10-07 | 1,914 Common Stock | (F4) The securities are held by China IV. Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. (F5) Fully vested and exercisable. |